Feb 16, 2022
Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants 2

Breakthrough DNA vaccine, Alveavax, enters pre-clinical testing for Omicron & BA.2 variants. Alvea, a startup biotechnology company, today announced that it will begin to develop, test, and deliver DNA vaccines at scale to low and middle income countries with limited access to existing vaccine options.